Applied precision medicine in metastatic pancreatic ductal adenocarcinoma

BACKGROUND: Metastatic pancreatic ductal adenocarcinoma (mPDAC) bears a dismal prognosis due to the limited activity of systemic chemotherapy. In our platform for precision medicine, we aim to offer molecular-guided treatments to patients without further standard therapy options. METHODS: In this si...

Descripción completa

Detalles Bibliográficos
Autores principales: Taghizadeh, Hossein, Müllauer, Leonhard, Mader, Robert M., Schindl, Martin, Prager, Gerald W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357054/
https://www.ncbi.nlm.nih.gov/pubmed/32699558
http://dx.doi.org/10.1177/1758835920938611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357054/
https://www.ncbi.nlm.nih.gov/pubmed/32699558
http://dx.doi.org/10.1177/1758835920938611

Ejemplares similares